Chemotherapeutic agent 5-fluorouracil increases survival of SOD1 mouse model of ALS

Rando, A. ; de la Torre, M. (Universidad de Zaragoza) ; Martinez-Muriana, A. ; Zaragoza, P. (Universidad de Zaragoza) ; Musaro, A. ; Hernández, S. ; Navarro, X. ; Toivonen, J.M. (Universidad de Zaragoza) ; Osta, R. (Universidad de Zaragoza)
Chemotherapeutic agent 5-fluorouracil increases survival of SOD1 mouse model of ALS
Resumen: Amyotrophic lateral sclerosis (ALS) is a lethal motor neuron disease with no cure. Currently there are only two ALS drugs approved by the FDA, both with a limited therapeutic effect. In the search for drug candidates for ALS, we studied the effect of known stem cell mobilizing agents (treatment) and antimetabolite 5-fluorouracil (5-FU) (anti-treatment) in SOD1G93A model of ALS. Surprisingly, we found that anti-cancer drug 5-FU increases lifespan, delays the disease onset and improves motor performance in ALS mice. Although we were not able to demonstrate the mechanistic basis of the beneficial 5-FU action in ALS mice, our findings suggest that 5-FU or similar drugs are possible drug candidates for the treatment of motor neuron diseases through drug repurposing.
Idioma: Inglés
DOI: 10.1371/journal.pone.0210752
Año: 2019
Publicado en: PLoS ONE 14, 1 (2019), e0210752 [16pp]
ISSN: 1932-6203

Factor impacto JCR: 2.74 (2019)
Categ. JCR: MULTIDISCIPLINARY SCIENCES rank: 27 / 71 = 0.38 (2019) - Q2 - T2
Factor impacto SCIMAGO: 1.023 - Multidisciplinary (Q1)

Financiación: info:eu-repo/grantAgreement/ES/FIS/PI14-00947
Financiación: info:eu-repo/grantAgreement/ES/FIS/PI17-00949
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/CB06-05-1105
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/RD12-0019-0011
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/RD16-0011-0035
Tipo y forma: Article (Published version)
Área (Departamento): Área Genética (Dpto. Anatom.,Embri.Genét.Ani.)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Exportado de SIDERAL (2023-02-10-13:59:55)

Este artículo se encuentra en las siguientes colecciones:

 Record created 2019-01-31, last modified 2023-02-10

Versión publicada:
Rate this document:

Rate this document:
(Not yet reviewed)